• Likely source for global M. chimaera infection identified

    Scientists from a European Consortium reconstructed a global Mycobacterium chimaera outbreak by whole genome sequencing. The report has identified contaminated heater-cooler units as the likely source of the infection.

    Press Release

  • Molecules directed against tumor cells patented

    Researchers at the ImmunoSensation cluster of excellence at the University of Bonn have managed to do what many scientists dream of: together with researchers from the USA, they have patented new molecules that allow the immune system to be directed against tumor cells.

    Press Release

  • How an Ebola vaccine candidate activates our immune system

    In 2016, a clinical phase I trial on a potential vaccine against the dreaded Ebola virus was successfully completed. In a further trial, DZIF scientists have now shown in detail how our immune systems react to the tested vaccine "rVSV-ZEBOV" for the first time.

    Press Release

  • A list of pathogens sets priorities for antibiotic research

    The WHO has published a list of 12 bacteria groups which are to be given priority for future new antibiotic research and development. DZIF scientists at the University of Tübingen were substantially involved in developing this priority list.

    Press Release

  • New malaria vaccine effective in clinical trial

    Researchers of the University of Tübingen and DZIF in collaboration with the biotech company Sanaria Inc. have demonstrated in a clinical trial that a new vaccine for malaria called Sanaria® PfSPZ-CVac has been up to 100 percent effective when assessed at 10 weeks after last dose of vaccine.

    Press Release

News

  • 18 August 2017 - PRESS RELEASE

    On the way to developing a new active ingredient against chronic infections

    Chronic lung infections caused by the bacterium Pseudomonas aeruginosa require complex and, in most cases, long-term treatment with antibioticsnew medication is badly needed. Scientists at the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and the German Center for Infection Research (DZIF) are now improving an anti-infective active ingredient with a new mode of action. The starting point is a substance that can block the pathogenicity of the bacterium and weaken its protective biofilm. more ]